Nature

Cervical cancer kills 300,000 people a year — here’s how to speed up its elimination

Ovarian cancer mutational processes drive site-specific immune evasion

High-grade serous ovarian cancer is a genomically complex malignancy. Here the authors integrate whole-genome sequencing, single-cell RNA sequencing, digital histopathology and multiplexed immunofluorescence across 160 tumour sites from 42 patients, revealing that mutational processes shape site-specific immune evasion.

A persistent look at how tumours evade therapy

Genetics and anatomy sculpt immune-cell partners of ovarian cancer

Transgelin 2 guards T cell lipid metabolism and antitumour function

Mounting effective immunity against pathogens and tumours relies on the successful metabolic programming of T cells by extracellular fatty acids

Henrietta Lacks: science must right a historical wrong

NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity

Cancer-associated fibroblasts (CAFs) have a pivotal cancer-supportive role, yet CAF-targeted therapies are lacking

Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA

Emergence of drug resistance is the main cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC)

Functional evaluation and clinical classification of BRCA2 variants

Germline BRCA2 loss-of function variants, which can be identified through clinical genetic testing, predispose to several cancers

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

Single-cell whole-genome sequencing of 30,260 tumour genomes from 70 samples across 41 patients in the SPECTRUM cohort reveals that ongoing whole-genome doubling drives tumour evolvability and immune evasion in high-grade serous ovarian cancer.